Vinpotsetin-AKOS

General characteristics. Structure:

Active agent: Vinpocetine of 5,0 mg. Excipients: ascorbic acid - 0,5 mg, benzyl alcohol - 10,0 mg, sorbitol (sorbite) - 100,0 mg, tartaric acid - 5,0 mg, sodium disulphite (sodium metabisulphite) - 1,0 mg, water for injections - to 1 ml.

Pharmacological properties:

Pharmacodynamics. Improves metabolism of a brain, increasing consumption of glucose and oxygen brain tissue. Increases resistance of neurons to a hypoxia; strengthens glucose transport to a brain through a blood-brain barrier; transfers process of disintegration of glucose to energetically more economical, aerobic way; selectively blocks kaltsiyzavisimy phosphodiesterase; increases concentration of adenosinemonophosphate (AMF), a cyclic guanozinmonofosfat (tsGMF) and adenosinetriphosphate (ATP) in a brain. Strengthens exchange of noradrenaline and serotonin in a brain, has antioxidant effect. Reduces aggregation of thrombocytes and the increased viscosity of blood; increases the deforming ability of erythrocytes and blocks utilization by adenosine erythrocytes; promotes increase in return of oxygen erythrocytes. Improves a brain blood stream; reduces resistance of vessels of a brain without essential change of indicators of system blood circulation. Does not render effect of "burglarizing" and strengthens blood supply, first of all, in ischemic sites of a brain. Gets through a placental barrier.

Pharmacokinetics. Therapeutic concentration at parenteral administration in plasma - 10-20 ng/ml, distribution volume – 5,3 l/kg. Communication with proteins of plasma – 66%, clearance – 66,7 l/h, exceeds the plasma volume of a liver (50 l/h) that demonstrates extrarenal metabolism. The elimination half-life makes 4-5 h. Easily gets through gistogematichesky barriers (including a blood-brain barrier), into breast milk (about 0,25% during 1 h). It is removed by kidneys and intestines in the ratio 3: 2.

Indications to use:

- reduction of expressiveness of neurologic and mental symptoms at various forms of insufficiency of cerebral circulation (including an ischemic stroke, a recovery stage of a hemorrhagic stroke, an effect of the had stroke; tranzitorny ischemic attack; vascular dementia; vertebrobazilyarny insufficiency; atherosclerosis of vessels of a brain; posttraumatic and hypertensive encephalopathy);
- chronic diseases of a choroid of an eye and vessels of a retina (including occlusion of the central artery or vein of a retina);
- decrease in auditory acuity of perceptual type, Menyer's disease, idiopathic sonitus.

Route of administration and doses:

Drug is intended only for intravenous drop infusion, to enter slowly (speed of infusion should not exceed 80 thaws/min.). For infusion preparation 
it is possible to use the solution of sodium of chloride of 0,9% or solutions containing a dextrose. 
Initial daily dose of 20 mg in 500 ml of solution of sodium of chloride of 0,9% or the solutions containing a dextrose. At good tolerance within 2-3 days, the dose is raised to maximum – 1 mg/kg/days.
The average duration of treatment is 10-14 days. 
At diseases of a liver or kidneys of dose adjustment it is not required.

Features of use:

At parenteral administration by a sick diabetes mellitus it is necessary to control the content of glucose in blood since solution contains sorbitol, patients with cardial pathology cannot enter in/in because of danger of development of arrhythmia (up to fibrillation of ventricles).

Side effects:

Decrease in the ABP. Seldom - tachycardia, premature ventricular contraction, delay of intra ventricular conductivity. At parenteral administration: dizziness, feeling of heat, a dermahemia of the person, nausea, thrombophlebitis in an injection site. Overdose. Treatment: gastric lavage, reception of absorbent carbon, symptomatic treatment.

Interaction with other medicines:

Increases risk of development of hemorrhagic complications against the background of a geparinoterapiya. Vinpocetine solution for injections pharmaceutical is incompatible with heparin.

Contraindications:

- an acute phase of a hemorrhagic stroke, heavy coronary heart disease, heavy disturbances of a heart rhythm, hypersensitivity to any of drug components;
- pregnancy (perhaps placental bleeding and spontaneous abortions probably as a result of strengthening of placental blood supply);
- breastfeeding period;
- age up to 18 years.
Before drug use surely consult with the doctor. 
Use at pregnancy Use at pregnancy is contraindicated.
In the period of a lactation it is necessary to stop breastfeeding.

Storage conditions:

In the place protected from light, at a temperature from 15 to 25 °C. To store in the places unavailable to children. 
Period of validity 3 years. Not to use after the period of validity specified on packaging.

Issue conditions:

According to the recipe

Packaging:

In a cardboard pack of 10 ampoules complete with an ampoule knife.